Cholesterol efflux mediators in homozygous familial hypercholesterolemia patients on low-density lipoprotein apheresis

被引:18
|
作者
Nenseter, Marit S. [1 ,2 ]
Narverud, Ingunn [1 ,3 ,4 ]
Graesdal, Asgeir [5 ]
Bogsrud, Martin P. [1 ,6 ]
Aukrust, Pal [2 ,7 ,8 ]
Retterstol, Kjetil [1 ]
Ose, Leiv [1 ]
Halvorsen, Bente [2 ,8 ]
Holven, Kirsten B. [3 ]
机构
[1] Univ Oslo, Rikshosp, Oslo Univ Hosp, Lipid Clin, N-0027 Oslo, Norway
[2] Univ Oslo, Rikshosp, Oslo Univ Hosp, Internal Med Res Inst, N-0027 Oslo, Norway
[3] Univ Oslo, Inst Basic Med Sci, Dept Nutr, Oslo, Norway
[4] Oslo & Akershus Univ, Coll Appl Sci, Dept Hlth Nutr & Management, Fac Hlth Sci, Oslo, Norway
[5] Vestfold Ctr Internal Med, Sandefjord, Norway
[6] Alesund More & Romsdal Hlth Trust, Dept Internal Med, Alesund, Norway
[7] Univ Oslo, Rikshosp, Oslo Univ Hosp, Sect Clin Immunol & Infect Dis, N-0027 Oslo, Norway
[8] Univ Oslo, Fac Med, Oslo, Norway
关键词
ABCA1; ABCG1; Cholesterol efflux; Familial hypercholesterolemia; LDL apheresis; SR-BI; LDL-APHERESIS; TRANSPORT PATHWAY; ATHEROSCLEROSIS; CAPACITY; BINDING;
D O I
10.1016/j.jacl.2012.08.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND: Homozygous familial hypercholesterolemia (FH) is a rare disorder that may affect 1 person per million. Early initiation of aggressive cholesterol-lowering therapy is essential to prevent premature coronary heart disease. Selective removal of low-density lipoprotein (LDL) by LDL apheresis is a reliable method of treatment. METHODS AND RESULTS: Cholsterol efflux mediators of homozygous FH patients on weekly LDL apheresis were compared with those of age- and sex-matched heterozygous FH patients receiving oral medication only and with healthy control subjects. The data show that (1) compared with healthy controls, homozygous FH patients have significantly lower plasma levels of high-density lipoprotein cholesterol and apoA-I and significantly lower cholesterol-acceptor capacity of serum to promote cholesterol efflux from cholesterol-loaded THP-1 cells, combined with significantly lower peripheral blood mononuclear cell gene expression levels of ATP-binding cassette (ABC) transporter G1 and borderline-significantly lower levels of ABCA1 and scavenger receptor class B type I (SR-BI); and (2) compared with pre-LDL apheresis (a day before treatment), postapheresis (15 days later; on the day after the weekly treatment) levels of HDL cholesterol and apoA-I were significantly reduced, with no significant effect on cholesterol-acceptor capacity of serum or on peripheral blood mononuclear cell gene expression levels of the cellular transporters, except for a borderline-significant reduction in ABCA1 mRNA levels. CONCLUSIONS: The data showing decreased levels of cholesterol efflux mediators in plasma and cells may suggest that the overall cholesterol efflux capacity is impaired in homozygous FH patients. However, LDL apheresis may maintain cholesterol efflux capacity, despite a lowering levels of highdensity lipoprotein cholesterol and apoA-I. (C) 2013 National Lipid Association. All rights reserved.
引用
收藏
页码:109 / 116
页数:8
相关论文
共 50 条
  • [1] Low-density lipoprotein apheresis in homozygous familial hypercholesterolemia
    Mora, C
    Teruel, JL
    Navarro, JF
    AMERICAN JOURNAL OF CARDIOLOGY, 2001, 88 (02): : 202 - 203
  • [2] Pregnancy in a Woman with Homozygous Familial Hypercholesterolemia Not on Low-Density Lipoprotein Apheresis
    Fahed, Akl C.
    Nassar, Anwar H.
    AJP REPORTS, 2012, 2 (01): : 33 - 35
  • [3] Comparison of two low-density lipoprotein apheresis systems in patients with homozygous familial hypercholesterolemia
    Drouin-Chartier, Jean-Philippe
    Tremblay, Andre J.
    Bergeron, Jean
    Pelletier, Maude
    Laflamme, Nathalie
    Lamarche, Benoit
    Couture, Patrick
    JOURNAL OF CLINICAL APHERESIS, 2016, 31 (04) : 359 - 367
  • [4] Low Density Lipoprotein Apheresis in Pediatric Patients With Homozygous Familial Hypercholesterolemia
    Coker, Mahmut
    Ucar, Sema Kalkan
    Simsek, Damla Goksen
    Darcan, Sukran
    Bak, Mustafa
    Can, Sule
    THERAPEUTIC APHERESIS AND DIALYSIS, 2009, 13 (02) : 121 - 128
  • [5] The Low-Density Lipoprotein Receptor Genotype Is a Significant Determinant of the Rebound in Low-Density Lipoprotein Cholesterol Concentration After Lipoprotein Apheresis Among Patients With Homozygous Familial Hypercholesterolemia
    Drouin-Chartier, Jean-Philippe
    Tremblay, Andre J.
    Bergeron, Jean
    Lamarche, Benoit
    Couture, Patrick
    CIRCULATION, 2017, 136 (09) : 880 - 882
  • [6] Long-term effect of low-density lipoprotein apheresis in patients with homozygous familial hypercholesterolemia
    Makino, H
    Harada-Shiba, T
    THERAPEUTIC APHERESIS AND DIALYSIS, 2003, 7 (04) : 397 - 401
  • [7] Atorvastatin in low-density lipoprotein apheresis-treated patients with homozygous and heterozygous familial hypercholesterolemia
    Goldammer, A
    Wiltschnig, S
    Heinz, G
    Jansen, M
    Stulnig, T
    Hörl, WH
    Derfler, K
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2002, 51 (08): : 976 - 980
  • [8] Systematic Review of Low-Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia
    Wang, Anthony
    Richhariya, Akshara
    Gandra, Shravanthi R.
    Calimlim, Brian
    Kim, Lisa
    Quek, Ruben G. W.
    Nordyke, Robert J.
    Toth, Peter P.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2016, 5 (07):
  • [9] Low Density Lipoprotein Apheresis in Lebanese Pediatric Patients with Homozygous Familial Hypercholesterolemia
    Mourani, C. C.
    Hneidi, M.
    PEDIATRIC NEPHROLOGY, 2010, 25 (09) : 1943 - 1943
  • [10] Low-density lipoprotein apheresis for the treatment of familial hypercholesterolemia
    Khan, T.
    Chandra, K. M.
    Pham, B.
    VALUE IN HEALTH, 2008, 11 (03) : A208 - A209